Kidney Cancer

RAMPART shows early quality-of-life declines with adjuvant Imfinzi and Imjudo, improving over time, though later cognitive and pain effects emerge.

Keytruda plus Welireg lowered the risk of recurrence in high-risk clear cell kidney cancer after surgery.

Welireg plus Lenvima improved outcomes compared with versus Cabometyx in advanced clear cell renal cell carcinoma after immunotherapy.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

Five-year follow-up of cryoablation for small kidney tumors shows high recurrence-free rates and a minimally invasive option for select patients.

Rodney Haring discusses Indigenous navigation, partnerships and prevention strategies to reduce cancer disparities and improve equity in Native communities

Learn diagnosis, treatments, side effects and key questions to help guide shared decisions with your oncology team after stage 4 ccRCC diagnosis.

Stage 3 ccRCC is locally advanced but often treatable. Learn how it is diagnosed, treated, and managed to support informed decisions with your care team.

The U.S. FDA has issued an updated safety communication regarding two commonly used chemotherapy drugs, Xeloda and fluorouracil.

Stage 2 ccRCC is treated with surgery, and patients should discuss partial nephrectomy, adjuvant therapy, and follow-up care with their oncology team.

Receiving a diagnosis of stage 1 clear cell renal cell carcinoma can be a shock, but this is the most common and most treatable stage of kidney cancer

Chuck Stravin shares 10 practical, patient-centered tips for managing emotions, information, and routines in the first days after a cancer diagnosis.

Receiving a diagnosis of stage 4 renal cell carcinoma can be overwhelming, but the treatment landscape has changed in recent years. Learn more from CURE.

As kidney cancer survival improves, more patients report cognitive changes affecting memory, fatigue, and overall mental clarity

Stage 3 kidney cancer can be managed with surgery, immunotherapy and targeted therapy; knowing your options helps guide informed decisions.

Although most patients with localized kidney cancer have high cancer-specific survival, surveys show a gap between doctor and patient perceptions of cure.

Dr. Michael Staehler highlighted nutrition’s role in kidney cancer, noting that diet, stress management, and lifestyle can impact outcomes and well-being.

The FDA has granted fast track designation to ITM-94 as a diagnostic agent for the detection of the most common type of kidney cancer.

A real-world study found TKIs were the most common therapy for adults with metastatic renal cell carcinoma after prior immune checkpoint inhibitor use.

A study at IKCS finds higher BMI after kidney cancer diagnosis improves survival, while significant weight loss predicts poorer outcomes.

American Indian and Alaskan Native individuals face some of the highest kidney cancer burdens in the United States.

Patients with advanced renal cell carcinoma whose disease has progressed on first-line therapies may benefit from the combination of Fruzaqla and Tyvyt.

Dr. Ravi Munver discusses how minimally invasive techniques allow patients to preserve kidney function and practical guidance for navigating treatment.

Remote monitoring has been found to be associated with improved postsurgical recovery for patients with cancer.